Table 2.
Associations of age at diagnosis with the molecular characteristics of breast cancer (No. [%])
| Characteristics | 40‐59 | ~39 | 60~ | ||
|---|---|---|---|---|---|
| No. (%) | No. (%) | OR (95% CI)a | No. (%) | OR (95% CI)a | |
| DNAm age | |||||
| DNAmAge (per 10 y) | 486 (100) | 75 (100) | 0.78 (0.66, 0.93) | 492 (100) | 1.34 (1.22, 1.48) |
| AgeAccel | |||||
| ≤0 | 295 (60.7) | 34 (45.3) | 1.00 (reference) | 348 (70.7) | 1.00 (reference) |
| >0 | 191 (39.3) | 41 (54.6) | 2.21 (1.12, 4.12) | 144 (29.3) | 0.49 (0.35, 0.67) |
| Basal‐like subtype | |||||
| No | 376 (77.4) | 56 (77.7) | 1.00 (reference) | 427 (86.6) | 1.00 (reference) |
| Yes | 110 (22.6) | 19 (25.3) | 1.35 (0.48, 3.78) | 66 (13.4) | 0.51 (0.35, 0.73) |
| Risk stratification | |||||
| Low risk | 122 (35.4) | 26 (42.6) | 1.00 (reference) | 136 (42.1) | 1.00 (reference) |
| High risk | 223 (64.6) | 35 (57.4) | 0.61 (0.33, 1.12) | 187 (57.9) | 0.72 (0.50, 1.03) |
| TP53 mutation | |||||
| No | 259 (58.5) | 47 (68.1) | 1.00 (reference) | 309 (70.9) | 1.00 (reference) |
| Yes | 184 (41.5) | 22 (31.9) | 0.48 (0.23, 0.99) | 127 (29.1) | 0.63 (0.44, 0.92) |
| PIK3CA mutation | |||||
| No | 306 (69.1) | 51 (73.9) | 1.00 (reference) | 275 (63.1) | 1.00 (reference) |
| Yes | 137 (30.9) | 18 (26.1) | 0.69 (0.33, 1.33) | 161 (36.9) | 1.24 (0.90, 1.73) |
| GATA3 mutation | |||||
| No | 375 (84.7) | 52 (75.4) | 1.00 (reference) | 395 (90.6) | 1.00 (reference) |
| Yes | 68 (15.3) | 17 (24.6) | 2.19 (1.07, 4.37) | 41 (9.4) | 0.39 (0.24, 0.64) |
| MLL3 mutation | |||||
| No | 412 (93.0) | 66 (95.7) | 1.00 (reference) | 380 (87.2) | 1.00 (reference) |
| Yes | 31 (7.0) | 3 (4.3) | 0.09 (0.01, 0.45) | 56 (12.8) | 1.45 (0.94, 2.23) |
| CDH1 mutation | |||||
| No | 389 (87.8) | 68 (98.5) | 1.00 (reference) | 352 (80.7) | 1.00 (reference) |
| Yes | 54 (12.2) | 1 (1.5) | 0.26 (0.02, 1.28) | 84 (19.3) | 1.90 (1.13, 3.25) |
| MAP3K1 mutation | |||||
| No | 414 (93.5) | 67 (97.1) | 1.00 (reference) | 386 (88.5) | 1.00 (reference) |
| Yes | 29 (6.5) | 2 (2.9) | 0.41 (0.06, 1.45) | 50 (11.5) | 1.61 (0.96, 2.73) |
AgeAccel, Age Acceleration; DNAm Age, DNA methylation age, DNAmAge minus Chronological Age. Risk stratification was grouped by median value of risk score, patients were predicted as high risk group if risk score larger than 0.033, others were predicted as low risk group.
Odds ratio adjusted for race, tumor size, node status, ER status, HER2 status. Bold values mean P < 0.05.